Ascendis Pharma (ASND) Receives a Buy from Stifel Nicolaus


Stifel Nicolaus analyst Adam Walsh reiterated a Buy rating on Ascendis Pharma (NASDAQ: ASND) yesterday and set a price target of $81. The company’s shares closed yesterday at $76.09, close to its 52-week high of $76.99.

According to TipRanks.com, Walsh is a 4-star analyst with an average return of 17.4% and a 53.5% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Galmed Pharmaceuticals, and Reata Pharmaceuticals.

Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $77.75.

See today’s analyst top recommended stocks >>

Based on Ascendis Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $50.85 million. In comparison, last year the company had a GAAP net loss of $33.82 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts